Inflammatory bowel disease

Common Name(s)

Inflammatory bowel disease, IBD

Inflammatory bowel disease (IBD) is the chronic redness and swelling (inflammation) of all or part of the digestive tract, which includes the esophagus, stomach, small intestine, and large intestine. The exact cause of the inflammation in IBD is not known, but a person’s immune system and genetic makeup are both thought to play a role. Risk factors for developing IBD includes older age, Caucasian (white) ethnic background, cigarette smoking, and using certain medications.

The two main types of IBD are ulcerative colitis and Crohn’s disease. Ulcerative colitis is a condition that causes inflammation and sores (ulcers) on the inside lining of the large intestine. Crohn’s disease causes inflammation that spreads deep into the affected tissue and usually affects the large intestine, the small intestine, or both. Symptoms of IBD vary and depend on the location and severity of the inflammation. Symptoms may include diarrhea, fever and fatigue, abdominal pain and cramping, blood in the stool, reduced appetite, and unintended weight loss.

To diagnose IBD, a physician will first rule out other possible causes of the symptoms. To confirm a diagnosis of IBD, your doctor may order a blood test to look for low red blood cells (anemia), a procedure that uses a small camera to examines your digestive tract for signs of IBD (endoscopy or colonoscopy), and imaging tests (X-rays, CT, or MRI) to look for evidence of IBD. Treatment includes the use of medications that reduces the immune system’s response and decreases the inflammation in the digestive tract. In severe cases, surgery may be needed. Although this condition is serious, affected individuals can live a normal life with proper treatment and care. If you or your child has been diagnosed with IBD, talk with your doctor about the current treatment options.

Source: Advocacy organizations associated with the condition.

 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Inflammatory bowel disease" for support, advocacy or research.

Crohn's & Colitis Foundation of America, Inc.

CCFA's mission is to cure Crohn's disease and ulcerative colitis and to improve the quality of life of children and adults affected by these diseases.

Last Updated: 8 Apr 2014

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Inflammatory bowel disease" for support, advocacy or research.

Crohn's & Colitis Foundation of America, Inc.

CCFA's mission is to cure Crohn's disease and ulcerative colitis and to improve the quality of life of children and adults affected by these diseases.

http://www.ccfa.org

Last Updated: 8 Apr 2014

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Inflammatory bowel disease" returned 2608 free, full-text research articles on human participants. First 3 results:

Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study.
 

Author(s): Devin Abrahami, Antonios Douros, Hui Yin, Oriana Hoi Yun Yu, Christel Renoux, Alain Bitton, Laurent Azoulay

Journal:

 

To assess whether the use of dipeptidyl peptidase-4 inhibitors is associated with the incidence of inflammatory bowel disease in patients with type 2 diabetes.

Last Updated: 31 Dec 1969

Go To URL
Acetarsol Suppositories: Effective Treatment for Refractory Proctitis in a Cohort of Patients with Inflammatory Bowel Disease.
 

Author(s): Christopher J Kiely, Angela Clark, Joya Bhattacharyya, Gordon W Moran, James C Lee, Miles Parkes

Journal: Dig. Dis. Sci.. 2018 04;63(4):1011-1015.

 

Management of proctitis refractory to conventional therapies presents a common clinical problem. The use of acetarsol suppositories, which are derived from organic arsenic, was first described in 1965. Data concerning clinical efficacy and tolerability are very limited.

Last Updated: 31 Dec 1969

Go To URL
Health-Risk Behaviors and Chronic Conditions Among Adults with Inflammatory Bowel Disease - United States, 2015 and 2016.
 

Author(s): Fang Xu, James M Dahlhamer, Emily P Zammitti, Anne G Wheaton, Janet B Croft

Journal:

 

Inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis, involves chronic inflammation of the gastrointestinal tract. In 2015, an estimated 3.1 million adults in the United States had ever received a diagnosis of IBD (1). Nationally representative samples ...

Last Updated: 31 Dec 1969

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Inflammatory bowel disease" returned 983 free, full-text review articles on human participants. First 3 results:

Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease.
 

Author(s): Mark Fleisher, Jan Marsal, Scott D Lee, Laura E Frado, Alyssa Parian, Burton I Korelitz, Brian G Feagan

Journal: Dig. Dis. Sci.. 2018 04;63(4):825-833.

 

Approximately 15-20% of ulcerative colitis patients and 20-40% of those with Crohn's disease experience extraintestinal manifestations (EIMs) of their inflammatory bowel disease (IBD). Clinicians who treat IBD must manage EIMs affecting multiple organs that variably correlate with ...

Last Updated: 31 Dec 1969

Go To URL
[Effect of Immunomodulators and Biologic Agents on Malignancy in Patients with Inflammatory Bowel Disease].
 

Author(s): Jee Hyun Kim, Ji Won Kim

Journal: Korean J Gastroenterol. 2017 Oct;70(4):162-168.

 

Immunosuppressive agents and biological agents are widely used for therapy in patients with inflammatory bowel disease (IBD). However, these therapies may be associated with an increased risk of malignancy. There is evidence that exposure of the therapeutic agents such as thiopurine ...

Last Updated: 31 Dec 1969

Go To URL
Inflammation and Aortic Stiffness: An Individual Participant Data Meta-Analysis in Patients With Inflammatory Bowel Disease.
 

Author(s): Luca Zanoli, Pierre Boutouyrie, Pasquale Fatuzzo, Antonio Granata, Paolo Lentini, Kadir Oztürk, Maria Cappello, Eleni Theocharidou, Antonino Tuttolomondo, Antonio Pinto, Calogero Cammà, Anna Licata, Julien Blanco, Stefania Rastelli, Gaetano Inserra, Pietro Castellino, Stephane Laurent

Journal:

 

The recent finding that aortic pulse wave velocity (aPWV) is increased in patients with inflammatory bowel disease may explain why the cardiovascular risk is increased despite the low prevalence of traditional cardiovascular risk factors. We aimed to test whether inflammation is associated ...

Last Updated: 31 Dec 1969

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Inflammatory Bowel Disease Registry in Daegu-Gyeongbuk
 

Status: Recruiting

Condition Summary: Idiopathic Chronic Inflammatory Bowel Disease

 

Last Updated: 23 Jul 2016

Go to URL

Last Updated: 13 Sep 2017

Go to URL
Rheumatological Manifestations in Inflammatory Bowel Diseases
 

Status: Not yet recruiting

Condition Summary: Inflammatory Bowel Diseases

 

Last Updated: 1 Apr 2018

Go to URL